Butalbital APAP, which is also prescribed as Axocet, is commonly used to treat tension headaches or pain caused by the constricting of muscles. It is most often prescribed in conjunction with a pain reliever and sometimes caffeine. Butalbital APAP is a barbiturate.
Butalbital APAP is not appropriate for everyone. A thorough medical history should be assessed prior to prescribing this medication. Patients with a medical history which includes heavy drinking, porphyria, liver disease, kidney disease, a history of drug abuse, or suicidal ideation may not be able to take Butalbital APAP or may require careful monitoring while undergoing drug therapy with this medication, depending on the condition and the severity of the condition. This medication is not appropriate for children under 12 years of age.
The American Food and Drug Administration rated this medication as a pregnancy risk category C. Butalbital APAP has been proven to cause harm or birth defects in unborn babies. This medication has been proven to pass through the mother’s breast milk and affect a nursing baby. The prescribing physician should not prescribe this medication to women who are pregnant or nursing, or who are likely to become pregnant.
There is a risk of side effects associated with Butalbital APAP, some of which are severe. A patient who is experiencing a serious side effect or an allergic reaction should seek immediate emergency medical intervention. An allergic reaction will present with symptoms which include facial swelling, including swelling of the lips, mouth, tongue, or throat, hives, and difficulty breathing. Other serious side effects which require emergency medical care include symptoms such as jaundice, severe nausea, abdominal pain, unusual bleeding, easy bruising, or extreme fatigue.
Other less serious side effects typically do not require emergency medical intervention but should be reported to the prescribing physician. Patients should be encouraged to report all side effects. Less serious side effects include symptoms such as headache, drowsiness, dry mouth, loss of appetite, nausea, vomiting, abdominal discomfort, dizziness, fatigue, lightheadedness, confusion, agitation, irritability, excitability, rash, itching, shortness of breath, nervousness, anxiety, or a feeling of intoxication. Less serious side effects can often be reduced to a more tolerable level by reducing the dosage of Butalbital APAP.
Butalbital APAP should be taken exactly as it has been prescribed by the physician. If the patient misses a dose, the dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to avoid the potential for an overdose. The patient should never take a double dose of this medication. If an overdose is suspected, the patient should seek immediate emergency medical attention. An overdose will present with symptoms such as sweating, nausea, vomiting, abdominal pain, seizures, drowsiness, decreased breathing, dizziness, fainting, confusion, irregular heart beat, coma, and death.
There is a risk of negative drug interactions associated with Butalbital APAP. A thorough medical history should be understood prior to prescribing this medication. Patients should be urged to inquire with the prescribing physician before taking any new medications, including over the counter medications and herbal remedies. Medications with known interactions with butalbital APAP include antidepressants, alcohol, sedatives, muscle relaxants, narcotic pain relievers, cough and cold medicine, anti-anxiety medications, and medicine which has been proven to cause drowsiness. Patients who have taken an MAOI within 14 days can not take butalbital APAP, as life threatening interactions may occur.
This medication has been proven to be habit forming, even in patients with no previous history of addiction problems. Care should be taken to wean patients off this medication if they use it for longer than a few days.
Butalbital apap has the following structural formula:
• Molecular formula of butalbital apap is C8H9NO2
• Chemical IUPAC Name is N-(4-hydroxyphenyl)acetamide
• Molecular weight is 151.163 g/mol
• Butalbital apap available : 50-325mg tablets
©2007-2017 Medicalook.com All rights reserved